How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

It is rare that an ABC Movie of the Week endures. Buzz Kulik’s 1971 “Brian’s Song” is a notable exception. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Stacy Wentworth, MD
Clinical associate, Department of Radiation Oncology, Duke University School of Medicine; Host and producer, Less Radical podcast, which covers the story of Bernie Fisher and the NSABP
Table of Contents

YOU MAY BE INTERESTED IN

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM. 
The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.
Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment. 
The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. 
Stacy Wentworth, MD
Clinical associate, Department of Radiation Oncology, Duke University School of Medicine; Host and producer, Less Radical podcast, which covers the story of Bernie Fisher and the NSABP

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login